Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Inclusion Criteria: 1. Aged between 18 and 75 years; 2. Understand the research procedure and content, and voluntarily sign written informed consent; 3. Patients with clinical stage IIA-IIIB esophageal cancer were assessed by endoscopic ultrasonography, CT/MRI and other imaging. 4. Esophageal surgery experts believe that patients with potentially resectable esophageal cancer 5. No blood transfusion was received 3 months before enrollment; 6. ECOG PS score: 0-1. Exclusion Criteria: * Patients meeting any of the following criteria are not eligible for inclusion: 1. Women who are pregnant or breastfeeding; 2. previous or concurrent malignancy; 3. Participated in clinical trials of other drugs within four weeks; 4. Have a history of immune deficiency, or other acquired or congenital immune deficiency diseases, or have a history of organ transplantation, or have a history of serious chronic autoimmune diseases, such as systemic lupus erythematosus, etc. 5. Patients with hypersensitivity to human or mouse monoclonal antibodies; 6. Those who have a history of psychotropic drug abuse and cannot get rid of it or have mental disorders; 7. According to the judgment of the researcher, there are serious concomitant diseases that endanger the patient's safety or affect the patient's ability to complete the study.